CN1051923C - 局部给药制剂 - Google Patents
局部给药制剂 Download PDFInfo
- Publication number
- CN1051923C CN1051923C CN94103562A CN94103562A CN1051923C CN 1051923 C CN1051923 C CN 1051923C CN 94103562 A CN94103562 A CN 94103562A CN 94103562 A CN94103562 A CN 94103562A CN 1051923 C CN1051923 C CN 1051923C
- Authority
- CN
- China
- Prior art keywords
- local administration
- vasoconstrictor
- disodium cromoglycate
- preparation
- disodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000006208 topical dosage form Substances 0.000 title 1
- 229960000265 cromoglicic acid Drugs 0.000 claims abstract description 20
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000005526 vasoconstrictor agent Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000007923 nasal drop Substances 0.000 claims description 9
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 8
- 229960003291 chlorphenamine Drugs 0.000 claims description 8
- 239000011976 maleic acid Substances 0.000 claims description 8
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical group Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 claims description 6
- 239000006196 drop Substances 0.000 claims description 6
- 229960004760 naphazoline hydrochloride Drugs 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 abstract description 2
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 7
- 206010039085 Rhinitis allergic Diseases 0.000 description 7
- 201000010105 allergic rhinitis Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000158526 Nasalis Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- YGRFXPCHZBRUKP-UHFFFAOYSA-N Methoxamine hydrochloride Chemical compound Cl.COC1=CC=C(OC)C(C(O)C(C)N)=C1 YGRFXPCHZBRUKP-UHFFFAOYSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LPRLDRXGWKXRMQ-UHFFFAOYSA-N diphenylpyraline hydrochloride Chemical compound [Cl-].C1C[NH+](C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LPRLDRXGWKXRMQ-UHFFFAOYSA-N 0.000 description 1
- 229960002392 diphenylpyraline hydrochloride Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960004269 methoxamine hydrochloride Drugs 0.000 description 1
- MGCQZNBCJBRZDT-UHFFFAOYSA-N midodrine hydrochloride Chemical compound [H+].[Cl-].COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 MGCQZNBCJBRZDT-UHFFFAOYSA-N 0.000 description 1
- 229960002728 midodrine hydrochloride Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- LRCXRAABFLIVAI-UHFFFAOYSA-N norfenefrine Chemical compound NCC(O)C1=CC=CC(O)=C1 LRCXRAABFLIVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002503 norfenefrine hydrochloride Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940107333 phenergan Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- SVQFLMKSDLCPAY-UHFFFAOYSA-N tetrahydrozoline nitrate Chemical compound O[N+]([O-])=O.N1CCN=C1C1C2=CC=CC=C2CCC1 SVQFLMKSDLCPAY-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7553693 | 1993-04-01 | ||
| JP75536/93 | 1993-04-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1104498A CN1104498A (zh) | 1995-07-05 |
| CN1051923C true CN1051923C (zh) | 2000-05-03 |
Family
ID=13579038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94103562A Expired - Fee Related CN1051923C (zh) | 1993-04-01 | 1994-03-31 | 局部给药制剂 |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR100371622B1 (enExample) |
| CN (1) | CN1051923C (enExample) |
| TW (1) | TW259705B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893174B (zh) * | 2013-12-31 | 2015-09-02 | 山东天顺药业股份有限公司 | 一种治疗过敏性鼻炎的鼻喷雾剂 |
| CN103751188B (zh) * | 2013-12-31 | 2015-09-02 | 山东天顺药业股份有限公司 | 一种色甘萘甲那敏鼻喷雾剂 |
| CN103751189B (zh) * | 2014-01-01 | 2016-02-03 | 山东天顺药业股份有限公司 | 一种治疗鼻炎的药物组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1778E (fr) * | 1902-12-26 | 1903-10-24 | Paul Francois Gustave Goyard | Pasteurisation aérofuge du lait à l'abri de l'air, procédé dit: du bouchon de lait |
| JPS61106509A (ja) * | 1984-10-29 | 1986-05-24 | Fujisawa Pharmaceut Co Ltd | 鼻腔用医薬組成物 |
-
1994
- 1994-03-22 TW TW83102493A patent/TW259705B/zh active
- 1994-03-30 KR KR1019940006502A patent/KR100371622B1/ko not_active Expired - Fee Related
- 1994-03-31 CN CN94103562A patent/CN1051923C/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1778E (fr) * | 1902-12-26 | 1903-10-24 | Paul Francois Gustave Goyard | Pasteurisation aérofuge du lait à l'abri de l'air, procédé dit: du bouchon de lait |
| JPS61106509A (ja) * | 1984-10-29 | 1986-05-24 | Fujisawa Pharmaceut Co Ltd | 鼻腔用医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW259705B (enExample) | 1995-10-11 |
| KR100371622B1 (ko) | 2003-04-21 |
| CN1104498A (zh) | 1995-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1158994C (zh) | 含环丙沙星和地塞米松的局部悬浮制剂 | |
| CN1079672C (zh) | 口服阿来屈酯液体制剂 | |
| CN1149080C (zh) | 丙胺卡因及氟代烃气雾剂的制备 | |
| AU698236B2 (en) | Stabilized orthosilicic acid comprising preparation and biological preparation | |
| CN1174747C (zh) | 液体抗酸剂组合物 | |
| CN1114880A (zh) | 新的治疗剂 | |
| CN1128259A (zh) | 取代的甲磺酰胺硫酸盐及其溶剂化物的制备方法 | |
| CN1174754C (zh) | 液体抗酸组合物 | |
| CN1084408A (zh) | 环状粘着抑制剂 | |
| EP2090165A3 (en) | Antifungal composition with enhanced bioavailability | |
| US20200016138A1 (en) | Gel containing pirfenidone | |
| Gilsdorf et al. | Radionuclide evaluation of bile leakage and the use of subhepatic drains after cholecystectomy | |
| CN1051923C (zh) | 局部给药制剂 | |
| CN1794973A (zh) | 眼用防腐组合物 | |
| CN1111128A (zh) | 含吡氧噻嗪的皮肤表面抗炎组合物 | |
| WO2000016771A1 (fr) | Preparations liquides a usage externe contenant du cromoglycate de sodium et traitement ou prevention des symptomes allergiques oculaires | |
| CN1575185A (zh) | 用中等剂量的lhrh拮抗剂治疗痴呆和神经变性疾病 | |
| JP3264301B2 (ja) | 局所投与製剤 | |
| CN1150897C (zh) | 非甾体抗炎药物的可注射药物组合物 | |
| CN1198623C (zh) | 含环索奈德的含水药物组合物 | |
| CN1077790C (zh) | 青光眼治疗剂及眼压降低剂 | |
| CN1022023C (zh) | 含哌啶子基链烷醇衍生物的液体药物组合物的制备方法 | |
| CN1039284C (zh) | 治疗疼痛和增强疼痛解除作用的组合物 | |
| CN1080851A (zh) | 生长激素释放抑制因子的增强剂 | |
| JP2004059479A (ja) | 点眼剤組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |